Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 1027-1032

  Zhou, Zheng Tao ^a,b   Zhou, Fu Xiang ^a   Wei, Qing ^b   Zou, Li Yong ^c   Qin, Bin Fang ^b   Peng, Xu Shen ^b  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b CHINA THREE GORGES UNIVERSITY   (China)

^c Second Hospital of Yichang   (China)

Author keywords

Chemotherapy; Cisplatin; Endostar; Etoposide; Small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; RECOMBINANT ENDOSTATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; EXTENSIVE STAGE SMALL CELL LUNG CANCER; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINUS TACHYCARDIA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; DISEASE-FREE SURVIVAL; ENDOSTATINS; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80054743467     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1576-1     Document Type: Article

References (25)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistic, 2009 CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
2. P Micke A Faldum T Metz, et al. 2002 Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the study of lung cancer-what limits limited disease? Lung cancer 37 271 276 12234695 10.1016/S0169-5002(02)00072-7 (Pubitemid 35286725)
3. Simon C, Ginsberg RJ, Ruckdeschel JC (2001) Small-cell lung cancer. Chest Surg Clin N Am 11:165-188, ix (Pubitemid 32215730)
4. BE Johnson 2002 Management of small cell lung cancer Cancer Clin Chest Med 23 225 239 10.1016/S0272-5231(03)00070-4 (Pubitemid 34205617)
5. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153 10.1056/NEJM197108122850711 1:STN:280: DyaE38%2FgvVCqsQ%3D%3D
6. MS O'Reilly T Boehm T Shing, et al. 1997 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 277 285 9008168 10.1016/S0092-8674(00)81848-6 (Pubitemid 28015876)
7. O Kisker CM Becker D Prox, et al. 2001 Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model Cancer Res 61 7669 7674 11606410 1:CAS:528:DC%2BD3MXnvFSht70%3D (Pubitemid 32995064)
8. SS Yoon H Eto CM Lin, et al. 1999 Mouse endostatin inhibits the formation of lung and liver metastases Cancer Res 59 6251 6256 10626820 1:CAS:528:DC%2BD3cXktFynsw%3D%3D (Pubitemid 30035650)
9. M Dhanabal R Volk R Ramchandran, et al. 1999 Cloning, expression, and in vitro activity of human endostatin Biochem Biophys Res Commun 258 345 352 10329390 10.1006/bbrc.1999.0595 1:CAS:528:DyaK1MXjtVertro%3D (Pubitemid 29287054)
10. Yamaguchi N, Anand-Apte B, Lee M et al (1999) Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18:4414-4423 (Pubitemid 29391251)
11. M Dhanabal R Ramchandran MJ Waterman, et al. 1999 Endostatin induces endothelial cell apoptosis J Biol Chem 274 11721 11726 10206987 10.1074/jbc.274.17.11721 1:CAS:528:DyaK1MXislGlsrk%3D (Pubitemid 29197835)
12. M Rehn T Veikkola E Kukk-Valdre, et al. 2001 Interaction of endostatin with integrins implicated in angiogenesis Proc Natl Acad Sci U S A 98 1024 1029 11158588 10.1073/pnas.031564998 1:CAS:528:DC%2BD3MXht1SmsL0%3D (Pubitemid 32121180)
13. P Iughetti O Suzuki PH Godoi, et al. 2001 A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma Cancer Res 61 7375 7378 11606364 1:CAS:528:DC%2BD3MXnvFShsrY%3D (Pubitemid 32995018)
14. C Mundhenke JP Thomas G Wilding, et al. 2001 Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin Clin Cancer Res 7 3366 3374 11705849 1:CAS:528:DC%2BD3MXptFaju7g%3D (Pubitemid 33069967)
15. L Yang JW Wang Y Sun, et al. 2006 Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer [Article in Chinese] Zhonghua Zhong Liu Za Zhi 28 138 141 16750022
16. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
17. M Lucchi A Mussi G Fontanini, et al. 2002 Small cell lung carcinoma (SCLC): the angiogenic phenomenon Eur J Cardiothorac Surg 21 1105 1110 12048093 10.1016/S1010-7940(02)00112-4 (Pubitemid 34615629)
18. LG Presta H Chen SJ O'Connor, et al. 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593 4599 9377574 1:CAS:528:DyaK2sXmslKqtLg%3D (Pubitemid 27441066)
19. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528: DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
20. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
21. K Miller M Wang J Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 18160686 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D
22. Ready N, Dudek AZ, Wang XF et al (2007) CALGB 30306: a phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive-stage, small-cell lung cancer (ES-SCLC). J Clin Oncol 25:18s (suppl; abstr 7563). http://meeting.ascopubs.org/cgi/content/abstract/25/18-suppl/7563
23. DR Spigel FA Greco JD Zubkus, et al. 2009 Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with extensive-stage, small-cell lung cancer J Thorac Oncol 4 1555 1560 19875975 10.1097/JTO.0b013e3181bbc540
24. L Horn SE Dahlberg AB Sandler, et al. 2009 Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group study E3501 J Clin Oncol 27 6006 6011 19826110 10.1200/JCO.2009.23.7545 1:CAS:528: DC%2BC3cXhtVWisLo%3D
25. Y Ling Y Yang N Lu, et al. 2007 Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells Biochem Biophys Res Commun 361 79 84 17644065 10.1016/j.bbrc.2007.06.155 1:CAS:528:DC%2BD2sXotlWru7k%3D (Pubitemid 47102270)